Beyang

Beyang announced $30M in Series A financing on August 12, 2026. Beyang Therapeutics raised nearly $30 million in an oversubscribed Series A co-led by Legend Capital and Shanghai Healthcare Capital to advance its AI-driven drug discovery platform and pipeline.

Round details

The financing includes backing from Legend Capital, Shanghai Healthcare Capital, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, Harbor and Canton Capital, Root Venture Partners, YuanBio Venture Capital. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: $30M

How the company plans to use the capital

Beyang said the proceeds will be primarily used to accelerate the technological iteration of its core AI and Molecular Design and Optimization platform (ExCEED), advance key pipeline candidates through clinical and preclinical development, and further expand its international R&D and business development teams.

Why this matters for GTM teams

The Series A was oversubscribed, and existing investors Root Venture Partners and YuanBio Venture Capital continued to support the round.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Beyang Series A announcement.